TLR9 and glioblastoma: In this studyit was demonstrated that pIpC was well tolerated and may be a suitablecandidate for use in combined regimes.18 Another promising agent against GBM is the TLR9 agonist CpG, whichentered a phase I clinical trial for patients with recurrent GBM.19